Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

02-06-2021 | EULAR 2021 | Conference coverage | Video

COVID-19 Global Rheumatology Alliance study finds link between RA treatment and COVID-19 severity

Jeffrey Sparks and Zachary Wallace talk about the potential for COVID-19 being more severe in rheumatoid arthritis patients treated with rituximab or JAK inhibitors rather than TNF inhibitors (8:06).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

01-04-2020 | COVID-19 | Podcast | Article

The COVID-19 Global Rheumatology Alliance registry: What you need to know

14-08-2020 | COVID-19 | News

Glucocorticoids, not anti-cytokine therapies, may worsen COVID-19 outcomes

30-03-2021 | COVID-19 | News

Rituximab use may be a risk factor for severe COVID-19

01-03-2021 | COVID-19 | Feature | Article

COVID-19 vaccination in patients with rheumatic diseases
Image Credits